118 Altered intestinal barrier in psoriasis is associated with disease severity, gastrointestinal symptoms and presence of bacteria metabolites in the blood

Alterations of gut microbiota, intestinal barrier and the gut-brain axis may be involved in pathophysiology of functional gastrointestinal disorders. Our aim was to assess the prevalence of digestive tract symptoms and identify common variables potentially disrupting the gut-brain axis among participants of the Woodstock Festival Poland, 2017. In total 428 people filled in a questionnaire assessing health of their digestive tract. The investigator collected answers on an electronic device, while the study participant responded using a paper version of the same questionnaire. Liver and gallbladder related symptoms were the most prevalent among our study group (n = 266, 62%), however symptoms related to altered intestinal permeability were found to be the most intensive complaints. In females the intensity of gastrointestinal complaints was higher compared to men (p < 0.05), as well as the incidence of factors with the potential to alter gut-brain axis (p < 0.0001). Chronic psychological distress, intake of non-steroidal anti-inflammatory drugs (NSAIDs) and antibiotics, were the most common associations with gastrointestinal symptoms, which were the most prevalent in females. Further attention should be focused on stress as one of the main factors negatively influencing public health.

Download Full-text

Intestinal Barrier Dysfunction, Endotoxemia, and Gastrointestinal Symptoms: The ‘Canary in the Coal Mine’ during Exercise-Heat Stress?

Thermoregulation and Human Performance - Medicine and Sport Science ◽

10.1159/000151550 ◽

2008 ◽

pp. 61-73 ◽

Cited By ~ 62

Author(s):

G. Patrick Lambert

Keyword(s):

Heat Stress ◽

Coal Mine ◽

Gastrointestinal Symptoms ◽

Intestinal Barrier ◽

Barrier Dysfunction ◽

Intestinal Barrier Dysfunction

Download Full-text

Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report

Journal of Clinical Medicine ◽

10.3390/jcm9082353 ◽

2020 ◽

Vol 9 (8) ◽

pp. 2353

Author(s):

Gian Paolo Caviglia ◽

Alessandra Tucci ◽

Rinaldo Pellicano ◽

Sharmila Fagoonee ◽

Chiara Rosso ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Clinical Response ◽

Bifidobacterium Longum ◽

Gastrointestinal Symptoms ◽

Intestinal Barrier ◽

Response To Therapy ◽

Intestinal Barrier Function ◽

Control Group ◽

Placebo Control ◽

Irritable Bowel

Bifidobacterium longum (B. longum) ES1 is a probiotic strain capable of modulating microbiome composition, anti-inflammatory activity and intestinal barrier function. We investigated the use of B. Longum ES1 in the treatment of patients with diarrhoea-predominant irritable bowel syndrome (IBS-D). Sixteen patients were treated for 8 or 12 weeks with B. Longum ES1 (1 × 109 CFU/day). Serum zonulin and cytokines were measured at baseline (T0) and at the end of therapy (T1). Clinical response to therapy was assessed by IBS Severity Scoring System. Interleukin (IL)-6, IL-8, IL-12p70 and tumor necrosis factor (TNF) α levels decreased from T0 to T1, irrespective of treatment duration (p < 0.05), while zonulin levels diminished only in patients treated for 12 weeks (p = 0.036). Clinical response was observed in 5/16 patients (31%): 4/8 (50%) treated for 12 weeks and 1/8 (13%) treated for 8 weeks. Abdominal pain improved only in patients treated for 12 weeks (5/8 vs. 0/8, p = 0.025), while stool consistency improved regardless of therapy duration (p < 0.001). In conclusion, the results of this pilot study showed, in IBS-D patients treated for 12 weeks with B. longum ES1, a reduction in the levels of pro-inflammatory cytokines, and intestinal permeability as well as an improvement in gastrointestinal symptoms, but further studies including a placebo-control group are necessary to prove a causal link.

Download Full-text

Impairments in Protein Digestion and Absorption Attenuate the Anabolic Response to Feeding in Patients with Congestive Heart Failure (FS09-03-19)

Current Developments in Nutrition ◽

10.1093/cdn/nzz044.fs09-03-19 ◽

2019 ◽

Vol 3 (Supplement_1) ◽

Author(s):

Sarah Kirschner ◽

Nicolaas E P Deutz ◽

Iris Rijnaarts ◽

Steven W M Olde Damink ◽

Marielle P K J Engelen

Keyword(s):

Heart Failure ◽

Congestive Heart Failure ◽

Disease Severity ◽

Glucose Transport ◽

Membrane Integrity ◽

Gastrointestinal Symptoms ◽

Protein Digestion ◽

Anabolic Response ◽

Intestinal Membrane ◽

Small Intestinal

Abstract Objectives Gastrointestinal symptoms are prevalent extracardiac systemic manifestations of Congestive Heart Failure (CHF). We developed a comprehensive panel of methods to unravel gut dysfunction in CHF and its impact on the anabolic response to feeding. Methods We recruited 14 clinically stable CHF patients (ejection fraction: 33.9 ± 2.1, NYHA class: 2.3 ± 0.2) and 17 healthy controls matched for age and gender. Stable tracers of L-phenylalanine (PHE)-[ring-2H5] and L-tyrosine (TYR)-[13C9,15 N] were administered intravenously for 5 hours via primed constant and continuous infusion. After 2 hours, participants ingested a complete high protein meal containing L-PHE-[1–13C] and spirulina-[U-15 N]. We sampled blood throughout the study to analyze enrichments by LC-MS/MS. We calculated the anabolic response to feeding before and after correction for changes in protein digestion and absorption, assessed by spirulina degradation ratio (L-PHE-[15 N]/[1–13C]). Moreover, we measured small intestinal membrane integrity and active carrier-mediated glucose transport by urinary recovery of the orally ingested inert sugars lactulose, rhamnose, and 3-O-methyl-glucose. Disease severity was assessed by medical chart and history. Statistical analysis was performed by unpaired t-tests. Data are expressed as mean ± SEM. Results In CHF patients, protein digestion and absorption were reduced (0.66 ± 0.04 vs. 0.82 ± 0.04, P < 0.01), which further attenuated the anabolic response to feeding (28.3 ± 3.8 vs. 54.0 ±5.5 μmol/kg FFM/meal, P < 0.001). Disturbances in protein digestion and absorption as well as anabolic response in CHF were independent of disease severity. Small intestinal permeability and active carrier-mediated glucose transport did not differ between the groups indicating a preserved enterocyte function in CHF patients. Conclusions We hypothesize that enhancing protein digestion and absorption in patients with CHF can improve the availability of nutrients and protein anabolism. Funding Sources National Institutes of Health

Download Full-text

Screening for and combining serum intestinal barrier-related biomarkers to predict the disease severity of AECOPD

Annals of Palliative Medicine ◽

10.21037/apm-20-1060 ◽

2020 ◽

Vol 9 (6) ◽

pp. 70-70

Author(s):

Jiuheng Yin ◽

Shuai Wang ◽

Yuan Qiu ◽

Enlai Jiang ◽

Guangsheng Du ◽

...

Keyword(s):

Disease Severity ◽

Intestinal Barrier

Download Full-text

Association between gastrointestinal symptoms and disease severity in patients with COVID-19 in Tehran City, Iran

Gastroenterology Review ◽

10.5114/pg.2021.106245 ◽

2021 ◽

Author(s):

Elena Lak ◽

Seyed Sheikholeslami ◽

Mahmoud Ghorbi ◽

Mostafa Shafei ◽

Homayon Yosefi

Keyword(s):

Disease Severity ◽

Gastrointestinal Symptoms

Download Full-text

Association of autoantibodies to muscarinic acetylcholine receptors with gastrointestinal symptoms and disease severity in patients with postural orthostatic tachycardia syndrome

Immunologic Research ◽

10.1007/s12026-021-09256-7 ◽

2022 ◽

Author(s):

Yoko Sunami ◽

Keizo Sugaya ◽

Natsuki Miyakoshi ◽

Osamu Iwazaki ◽

Kazushi Takahashi

Keyword(s):

Disease Severity ◽

Acetylcholine Receptors ◽

Gastrointestinal Symptoms ◽

Muscarinic Acetylcholine Receptors ◽

Postural Orthostatic Tachycardia Syndrome ◽

Muscarinic Acetylcholine

Download Full-text

Clinical Characteristics of COVID-19 Patients with Gastrointestinal Symptoms

Archives of Iranian Medicine ◽

10.34172/aim.2021.21 ◽

2021 ◽

Vol 24 (2) ◽

pp. 131-138

Author(s):

Mahnaz Montazeri ◽

Nastaran Maghbouli ◽

Raika Jamali ◽

Alireza Sharifi ◽

Marzieh Pazoki ◽

...

Keyword(s):

Disease Severity ◽

Clinical Characteristics ◽

Laboratory Data ◽

Gastrointestinal Symptoms ◽

Chi Square ◽

Increased Risk ◽

Gi Symptoms ◽

Significant Difference ◽

Treatment Data ◽

Risk Of Disease

Background: We aimed to assess the gastrointestinal (GI) manifestations of patients with severe acute respiratory syndrome coronavirus 2 infection and determine factors predicting disease prognosis and severity among patients with GI symptoms. Methods: In this retrospective study, we evaluated laboratory confirmed (by real-time polymerase chain reaction) inpatient cases of coronavirus-associated disease 2019 (COVID-19), referred to Sina hospital, a tertiary educational hospital of Tehran University of Medical Sciences, from March 10 to May 20, 2020. Demographic and clinical characteristics, laboratory data, outcomes and treatment data were extracted and analyzed using SPSS version 20. Results: A total of 611 patients (234 women and 377 men) were included with 155 patients having GI symptoms. The most prevalent reported GI symptom was nausea/vomiting in 115 (18.8%) of patients. A total of 20 patients (3.2%) only had GI symptoms (without respiratory symptoms). There was no statistically significant difference in the clinical outcomes, disease severity, intensive care unit (ICU) admission and mortality between patients with and without GI symptoms. Aspartate Aminotransferase level was associated with 446% increased risk of disease severity (adjusted odds ratio: 5.46, 95% CI: 2.01 to 14.81) (P=0.040) among patients with GI symptoms. Additionally, we found that treatment with antibiotics in addition to mechanical ventilation was associated with increased survival among patients with GI symptoms (Pearson Chi square: 6.22; P value: 0.013). Conclusion: More attention should be paid to patients with only GI symptoms for early patient detection and isolation. Moreover, patients with GI manifestations are not exposed to higher rates of disease severity or mortality.

Download Full-text

Correlation between gastrointestinal symptoms and disease severity in patients with COVID-19: a systematic review and meta-analysis

BMJ Open Gastroenterology ◽

10.1136/bmjgast-2020-000437 ◽

2020 ◽

Vol 7 (1) ◽

pp. e000437 ◽

Cited By ~ 1

Author(s):

Jing Liu ◽

Min Cui ◽

Tao Yang ◽

Ping Yao

Keyword(s):

Systematic Review ◽

Publication Bias ◽

Disease Severity ◽

Meta Analysis ◽

Severe Disease ◽

Gastrointestinal Symptoms ◽

Exclusion Criteria ◽

Funnel Plot ◽

Gi Symptoms ◽

Significant Difference

ObjectiveTo study the correlation between gastrointestinal (GI) symptoms and disease severity in patients with COVID-19.DesignWe searched six databases including three Chinese and three English databases for all the published articles on COVID-19. Studies were screened according to inclusion and exclusion criteria. The relevant data were extracted and all the statistical analyses were performed using Revman5.3.ResultIn a meta-analysis of 9 studies, comprising 3022 patients, 479 patients (13.7%, 95% CI 0.125 to 0.149) had severe disease and 624 patients (14.7%, 95% CI 0.136 to 0.159) had GI symptoms. Of 624 patients with GI symptoms, 118 patients had severe disease (20.5%, 95% CI 0.133 to 0.276) and of 2397 cases without GI symptoms, 361 patients had severe disease (18.2%, 95% CI 0.129 to 0.235). Comparing disease severity of patients with and without GI symptoms, the results indicated: I²=62%, OR=1.21, 95% CI 0.94 to 1.56, p=0.13; there was no statistically significant difference between the two groups. The funnel plot was symmetrical with no publication bias.ConclusionCurrent results are not sufficient to demonstrate a significant correlation between GI symptoms and disease severity in patients with COVID-19.

Download Full-text